Minimally invasive versus open surgery for nonfunctioning pancreatic neuroendocrine tumors: a systematic review and meta-analysis
Open Access
- 22 November 2024
- journal article
- review article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (12) , 8250-8255
Abstract
Introduction: Nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) have been diagnosed increasingly often but still represent rare pancreatic neoplasms. Surgery is a potentially curative approach for patients with NF-PNETs. In recent years, minimally invasive surgery (MIS) has been applied more frequently for surgical resection of NF-PNETs. The evidence for using MIS for NF-PNETs is still being determined and controversial. Materials and Methods: PubMed, Cochrane Library, and the Web of Science database were searched systematically from its inception to July 2023. All studies comparing MIS versus open surgery (OPS) of NF-PNETs were included. The primary outcomes were the incidence of overall postoperative complications and pancreas-specific complications [postoperative pancreatic fistula (POPF) and delayed gastric emptying (DGE)]. The secondary measures were duration of operation, intraoperative blood loss, and length of postoperative hospital stay. Pooled results are presented as odds ratios (OR) or mean difference (MD) with a 95% CI. Results: Five observational studies with a total of 1178 patients were included in the final analysis. The meta-analysis indicated that MIS attained less intraoperative blood loss (MD=−58.59, 95% CI [−92.76 to −24.41], PPP=0.67), overall postoperative complications (OR=0.78, 95% CI [0.59–1.03], P=0.08), POPF (OR=0.99, 95% CI [0.66–1.47], P=0.94), and DGE (OR=0.58, 95% CI [0.58–1.42], P=0.67). Conclusions: This study demonstrates that minimally invasive surgery for NF-PNETs is safe and associated with a considerably shorter postoperative hospital stay. Further studies are needed to verify the evidence.Keywords
This publication has 9 references indexed in Scilit:
- Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasmsBritish Journal of Cancer, 2023
- Neuroendocrine tumors' patients treated with somatostatin analogue could complicate with emergencycholecystectomy2023
- Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from 68Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine TumorsJournal of Nuclear Medicine, 2021
- Pancreatic neuroendocrine tumours: conservative versus surgical managementBritish Journal of Surgery, 2021
- Minimally Invasive Versus Open Pancreatectomy for Right-Sided and Left-Sided G1/G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Multicenter Matched Analysis with an Inverse Probability of Treatment-Weighting MethodAnnals of Surgical Oncology, 2021
- Minimally invasive vs open pancreatectomy for nonfunctioning pancreatic neuroendocrine tumorsWorld Journal of Gastrointestinal Oncology, 2020
- Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weightingSurgical Endoscopy, 2020
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- Laparoscopic versus open distal pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors: a large single-center studySurgical Endoscopy, 2017